BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會

講師

Cheng-Yu Chen

Session 7 – Public Private Partnership for Precision Health

Date:22 July (Thursday)
Time:  12:20 – 13:50 (GMT+8)

Cheng-Yu Chen

Vice President, Taipei Medical University
Director, TMU Research Center for Artificial Intelligence in Medicine
Professor of Radiology, Department of Medicine, Taipei Medical University
Joint Professor of the Institute of Medicine, National Defense Medical College
Chair of Neuroradiology, Department of Medical Imaging, Taipei Medical University Hospital
President of Asian-Oceanian Society of Neuroradiology and Head & Neck Radiology (AOSNHNR)
Special Advisor to Editor and Editor-in-Chief of American Journal of Neuroradiology (AJNR)
Director, The Radiological Society of the Republic of China (Taiwan Radiological Society)

I received my medical degree in the School of Medicine, National Defense Medical Center, Taipei, Taiwan in 1985. My major academic and research interests are neuroscience and neuroimaging, particularly involving studies on ischemic stroke, brain tumor, drug abuse, and dementia. My professional appointments are: The Vice President, Taipei Medical University and The Director, Research Center of Artificial Intelligence in Medicine and Health (TAIMH), Taipei Medical University since 2019. The chair, Department of Medical Imaging, Taipei Medical University Hospital since 2013. I took the office of director of Imaging Research Center, Taipei Medical University in March 2014. I have served as an editorial board member of the American Journal of Neurology {AJNR) from 2001-2011. I was appointed the section editor, Classic Case, special consultant, AJNR in 2011. I was a member of the scientific program committee, RSNA from 2007-2012 and president elect, AOCNR, 2018. I have been engaged years in imaging research, especially Radiomics and Radiogenomics. Recently, two papers with impact factors exceeding 10 have been published by Clinical Cancer Research and Nature Communications. I have served as the Principal Investigator of integrated projects of the Ministry of Science and Technology three times from 2018 to 2020. My future plan is to build up an advanced imaging center equipped with high end scanners such as 7T animal MRI, 3T human MRI with 64 channel head coils and super high detector row CT center. The imaging cores will be incorporated with other basic science teams to probe neurological disease. My goal is to complete these platforms in a great medical University and hospitals.

.

Speech title & Synopsis

Bridging New Horizon of AI Innovation and Precision Practice

Lung cancer is the leading cause of cancer death in Taiwan. Even with the recent addition of new target therapies and immunotherapy, the five-year survival remains disappointed, only below 15%. Clinically, the process of imaging and pathological diagnosis, driver gene verification, and radiotherapy and multiple-line drug selection of lung cancer is a complex, labor-intensive, and resource-consuming task, challenging both physicians and patients, suggesting an apparent unmet need in combatting the lung cancer and also a huge socio-economic impact if a system, such as AI prediction models, can be built to fill the gaps.

The talk will feature an AI laboratory team from a medical university that wade through a process of developing useful image AI algorithms for lung cancer and beyond, under the grant support by Ministry of Science and Technology MOST), Taiwan, and collaboration with industries. The team is now named Deep-Rad. AI after going through initial phase of executing MOST project in establishing big lung cancer image data for AI application. Talk will include developing AI-based platforms, encompassing medical imaging diagnosis and prognosis prediction of lung cancer, AI-powered electronic medical record system, an AI platform for analysis of genetic risk, drug response, and prognosis of lung cancer, as well as AI-aided precision medicine and match-up clinical trial system in lung cancer. By employing high quality and curated clinical and image data, as well as collaborating with Health IT companies, hopefully the precision lung cancer AI systems can help optimize clinical pathway in the diagnosis and treatment of lung cancer, thus holding the values for academic research and industry-university application. Lastly, but not the least, we will share our new direction to go beyond the lung cancer and expand to precision healthy aging at the end of the talk.